Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib is a research paper published in JCI Insight (2017). On theSindex it has a DataRank of 3.4. It has been cited 93 times, with 65 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.681
From this paper's citation signal
Citation Network Contribution
2.7
From 58 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 65 citers.
NCI NIH HHS
Grant: P50 CA100632
NCI NIH HHS
Grant: P30 CA016672
National Institutes of Health
Grant: 5R01CA081554-09
B-cell repertoires in chronic lymphocytic leukemia
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
Additional file 1 of Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse